You are here: Industry Insights > Rova-T

News List

Rova-T programme discontinued following poor trial results europeanpharmaceuticalreview
September 03, 2019
A Phase III trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer demonstrated no survival benefit.
AbbVie Discontinues Rova-T Research and Development Program contractpharma
August 30, 2019
Phase 3 trial evaluating Rova-T as a first-line therapy for SCLC demonstrated no survival benefit for patients.
Billions spent, but AbbVie can't catch a break with Rova-T as it cans SCLC trial fiercebiotech
January 02, 2019
AbbVie announced Wednesday afternoon that it would stop enrollment in a phase 3 trial of its troubled cancer med, Rova-T, in lung cancer patients.....
AbbVie suffers fresh setback with lung cancer drug Rova-T pharmaphorum
December 10, 2018
AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.
AbbVie halts phase III TAHOE trial of Rova-T for SCLC pharmaceutical-technology
December 10, 2018
Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab Tesirine.....
AbbVie halts late-stage TAHOE study of Rova-T in small-cell lung cancer firstwordpharma
December 06, 2018
AbbVie on Wednesday announced that it was stopping enrolment of the Phase III TAHOE study assessing rovalpituzumab tesirine, also known as Rova-T, as a second-line treatment for patients with advanced small-cell lung cancer.
After Rova-T Failure, A Look at AbbVie’s Pipeline biospace
March 28, 2018
AbbVie announced that after the disappointment of Phase II clinical trials, it will not require the FDA to accelerate the approval of Rova-T for use in three-line recurrence/refractory (R/R) small cell lung cancer
AbbVie's shares fall nearly 12 percent after decision to scrap plan for accelerated FDA approval of Rova-T firstwordpharma
March 23, 2018
Shares in AbbVie fell nearly as much as 12 percent Thursday after the company said it will not seek accelerated FDA approval for the antibody-drug conjugate rovalpituzumab tesirine, also known as Rova-T